July 25, 2016
The United States Patent and Trademark Office has issued a composition of matter patent for trabodenoson in combination with a prostaglandin analogue for reducing IOP in patients with glaucoma, according to a press release.
U.S. patent No. 9,370,530 includes composition of matter intellectual property protection for the use of trabodenoson (Inotek) in combination with a prostaglandin analogue until 2031. The patent also includes composition of matter patents covering the trabodenoson compound in the U.S. until 2026 and abroad until 2025, and the crystalline formulation of trabodenoson used in eye drops in the U.S. until 2033.